Invivoscribe’s NPM1 MRD Assay is an NGS-based, targeted, deep-sequencing assay that detects and monitors DNA sequences specific to identified mutations from the primary sample identified at diagnosis with an allelic sensitivity level of 5×10-5. This assay identifies and reports mutation variants ‘A,’ ‘B’, ‘D’, and ‘Other’ in subjects with no overt evidence of disease.
In addition, the NPM1 MRD Assay can be multiplexed with the FLT3 ITD MRD Assay to improve throughput and reduce cost.
FLT3 ITD MRD Assay & NPM1 MRD Assay
Background
Principle of the Procedure
Invivoscribe’s targeted, deep-sequencing assays are easily implemented together, following identical, streamlined workflows. Designed for high-throughput laboratories, each kit configuration includes 24 master mixes, each containing a carefully-selected, unique dual-index to prevent cross-contamination due to barcode hopping. FLT3 ITD MRD Software and NPM1 MRD Software analysis is initiated through REST-API or command line interface. The data is output in a tab-separated value (TSV) file.
Key Benefits
- Allelic sensitivity level of 5×10-5
- Batch samples using previously isolated gDNA
- Baseline sample not required
- Flexibility to multiplex targets and up to 24 unique indexes to gain cost-efficiencies
- Identify and track of distinct FLT3-ITD and NPM1 mutations and/or insertions from a single sample
- Dockerized software enables highly portable, flexible and efficient sample analysis
- Compatible with multiple sequencing platforms
The NPM1 MRD Assay and NPM1 MRD Software are For Research Use Only (RUO).
Not intended for diagnostic purposes.
References
1. Dillon et al (2023) JAMA. 329(9):745-755.
2. Dillon et al (2024) JAMA Onc. 10(8):1104-1110.
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
